Says Gross tariff impacts of $20-$25 million expected to be fully mitigated through cost actions; $30-$40 million of additional cost-savings in 2025; Positive adjusted free cash flow with 25-30% of adjusted EBITDA conversion; Interest expense of $177 million following the company’s debt refinancing; Capital expenditures of $160-$170 million, excluding instruments under reagent rental agreements and integration costs. Comments taken from investor presentation slides.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QDEL:
- QuidelOrtho reports Q3 adjusted EPS 80c, consensus 47c
- QuidelOrtho sees FY25 adjusted EPS $2.00-$2.15, consensus $2.24
- QuidelOrtho receives FDA 510(k) clearance for VITROS hs Troponin I Assay
- Is QDEL a Buy, Before Earnings?
- QuidelOrtho Hold Rating: Impact of Debt Refinancing and Chinese Market Risks